Genetically predicted immune cells mediate the association between gut microbiota and neuropathy pain

Inflammopharmacology, Journal Year: 2024, Volume and Issue: 32(5), P. 3357 - 3373

Published: July 2, 2024

Previous observational studies have indicated a complex association between gut microbiota (GM) and neuropathic pain (NP). Nonetheless, the precise biological mechanisms underlying this remain unclear. Therefore, we adopted Mendelian randomization (MR) approach to investigate causal relationship GM including post-herpetic neuralgia (PHN), painful diabetic peripheral neuropathy (PDPN), trigeminal (TN), as well explore potential mediation effects of immune cells.

Language: Английский

---

E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy

European Journal of Pain, Journal Year: 2024, Volume and Issue: 29(1)

Published: Dec. 4, 2024

Abstract Background We report the efficacy and safety of E‐52862—a selective, sigma‐1 receptor antagonist—from phase 2, randomized, proof‐of‐concept studies in patients with moderate‐to‐severe, neuropathic, chronic postsurgical pain (CPSP) painful diabetic neuropathy (PDN). Methods Adult (CPSP [ N = 116]; PDN 163]) were randomized at a 1:1 ratio to 4 weeks treatment E‐52862 n 55]; 85]) or placebo 61]; 78]) orally once daily. Pain intensity scores measured using numerical rating scale from 0 (no pain) 10 (worst imaginable). The primary analysis population comprised who received study drug ≥1 baseline on‐treatment observation (full set). Results In CPSP, mean average was 6.2 for vs. 6.5 placebo. Week change (CFB) −1.6 –0.9 (least squares difference [LSMD]: −0.9; p 0.029). PDN, 5.3 5.4 CFB −2.2 –2.1 (LSMD: –0.1; 0.766). Treatment‐emergent adverse events (TEAEs) reported 90.9% E‐52862‐treated 76.7% placebo‐treated CPSP 34.1% 26.9% PDN. Serious TEAEs occurred only: E‐52862: 5.5%; placebo: 6.7%. Conclusions demonstrated superior relief after weeks. Reductions seen E‐52862; high response rates may have prevented differentiation between treatments. had acceptable tolerability both populations. Significance Statement These validate mode action E‐52862, selective antagonist. resulted clinically meaningful relief. reductions findings are relevant given that neuropathic is highly incapacitating, lacking effective treatments representing significant unmet medical need, support further development antagonists peripheral pain.

Language: Английский

---

The Neurological Implications of COVID-19: A Comprehensive Narrative Review

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: May 15, 2024

The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 revealed a huge number of problems as well discoveries in medicine, notably, regarding effects virus on central nervous system (CNS) and peripheral (PNS). This paper is narrative review that takes deep dive into complex interactions between NS. Therefore, this explains broad range neurological manifestations neurodegenerative diseases virus. It carefully considers routes through which reaches NS, including olfactory course, hematogenous route, are also covered when discussing virus's direct indirect mechanisms neuropathogenesis. Besides pathologies such stroke, encephalitis, Guillain-Barré syndrome, Parkinson's disease, multiple sclerosis, focus area given to challenges making diagnosis, treatment, management these conditions during pandemic. examines strategic interventional approaches utilized prevent disorders, ACE2 receptors implicated mediation COVID-19. detailed overview, combines research outputs with case data, directed at tackling challenge, view toward better patient care outcomes future.

Language: Английский

---

Role of Exercise on Neuropathic Pain in Preclinical Models: Perspectives for Neuroglia

Molecular Neurobiology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 24, 2024

Language: Английский

---

Peripheral Nerve Stimulation for Neuropathic Pain Management: A Narrative Review

Pain and Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 28, 2024

Language: Английский

---